MDS Proteomics to acquire Protana
The companies have already begun working together to systematically identify the biological function of hundreds of proteins and reveal their biological pathways, in order to design drugs that address the mechanism of diseases. The research is being conducted at two industrial-scale proteomics facilities located at MDS Proteomics' sites in Toronto, Canada and Odense, Denmark.
According to MDS Proteomics president and CEO Frank Gleeson, functional proteomics will become the "key driver" for discovering new drugs.
"MDS Proteomics has brought together the most comprehensive approach for industrializing protein identification, protein-protein interactions, and biological pathway analyses,'' Gleeson continued. "We have the cell pathway expertise of Dr. Anthony Pawson, the financial resources and clinical capabilities of MDS Inc., and early access to the most advanced mass spectrometry instruments through our relationship with MDS Sciex. We are clearly positioned at the forefront of pharmaceutical discovery."
Protana is a proteomics company that develops and applies biological mass spectrometry to pharmaceutical and biotechnological research.
MDS Proteomics has developed a proprietary functional proteomics technology platform that leverages advanced knowledge of protein function and protein pathways. The company is 88% owned by MDS Inc., an international health and life sciences company.
For more information, contact Frank Gleeson, President and CEO of MDS Proteomics, at 416-213-4083.
Edited by Jim Pomager
Assistant Editor, Drug Discovery Online